Sutro Biopharma (STRO) — Financial Flexibility Index
Sutro Biopharma (STRO) has a Financial Flexibility Index of -0.13x as of June 2026. Free cash flow of $-38.29 Million (operating CF $-38.29 Million minus capex $0.00) represents 0% of total liabilities ($297.78 Million). Check cash flow reinvestment rate of Sutro Biopharma to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Sutro Biopharma Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Sutro Biopharma across 10 annual periods. For the full cash flow conversion analysis, see STRO cash generation efficiency.
Annual Financial Flexibility Index for Sutro Biopharma (2016–2025)
Year-by-year free cash flow to debt coverage for Sutro Biopharma. Explore STRO operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.57x | $-175.54 Million | $-177.23 Million | $306.28 Million | ▼ -4.2% |
| 2024 | -0.55x | $-188.44 Million | $-191.54 Million | $342.61 Million | ▼ -64.6% |
| 2023 | -0.33x | $-107.30 Million | $-111.62 Million | $321.09 Million | ▼ -656.3% |
| 2022 | 0.06x | $11.41 Million | $3.55 Million | $189.90 Million | ▲ +108.0% |
| 2021 | -0.75x | $-66.36 Million | $-81.68 Million | $88.84 Million | ▲ +23.6% |
| 2020 | -0.98x | $-60.67 Million | $-67.80 Million | $62.06 Million | ▲ +6.9% |
| 2019 | -1.05x | $-61.54 Million | $-65.02 Million | $58.58 Million | ▼ -775.8% |
| 2018 | 0.16x | $14.24 Million | $12.68 Million | $91.60 Million | ▲ +169.0% |
| 2017 | -0.23x | $-33.76 Million | $-37.07 Million | $149.77 Million | ▼ -312.2% |
| 2016 | -0.05x | $-8.76 Million | $-13.15 Million | $160.18 Million | — |